A highly sensitive bioluminescent method for measuring allergen‐specific IgE in microliter samples

Dr Nadeau reports grants and other from NIAID, other from Novartis, personal fees and other from Regeneron, grants and other from FARE, grants from EAT, other from Sanofi, other from Astellas, other from Nestle, other from BeforeBrands, other from Alladapt, other from ForTra, other from Genentech, other from AImmune Therapeutics, other from DBV Technologies, personal fees from Astrazeneca, personal fees from ImmuneWorks, personal fees from Cour Pharmaceuticals, grants from Allergenis, grants from Ukko Pharma, other from AnaptysBio, other from Adare Pharmaceuticals, other from Stallergenes-Greer, other from NHLBI, other from NIEHS, other from EPA, other from WAO Center of Excellence, other from Iggenix, other from Probio, other from Vedanta, other from Centecor, other from Seed, from Immune Tolerance Network, from NIH, outside the submitted work; In addition, Dr Nadeau has a patent Inhibition of Allergic Reaction to Peanut Allergen using an IL-33 Inhibitor pending, a patent Special Oral Formula for Decreasing Food Allergy Risk and Treatment for Food Allergy pending, a patent Basophil Activation Based Diagnostic Allergy Test pending, a patent Granulocyte-based methods for detecting and monitoring immune system disorders pending, a patent Methods and Assays for Detecting and Quantifying Pure Subpopulations of White Blood Cells in Immune System Disorders pending, a patent Mixed Allergen Compositions and Methods for Using the Same pending, and a patent Microfluidic Device and Diagnostic Methods for Allergy Testing Based on Detection of Basophil Activation pending. Dr Galli reports grants from National Institutes of Health, USA, during the conduct of the study; other from Enable Biosciences, outside the submitted work; In addition, Dr Galli has a patent which discloses methods for performing a highly sensitive test for measuring IgE antibodies to certain allergens, using recombinant allergens. pending to Enable Biosciences. Dr Chinthrajah reports grants from NIAID, grants from CoFAR, grants from Aimmune, grants from DBV Technologies, grants from Astellas, grants from Regeneron, other from Alladapt, other from Genentech, other from Novartis, personal fees from Before Brands, outside the submitted work; Dr Reber reports grants from Institut National de la Santé et de la Recherche Médicale (INSERM), during the conduct of the study; grants and personal fees from Neovacs, outside the submitted work; In addition, Dr Reber has a patent WO2019197607 (A1) issued, a patent WO2019228674 (A1) issued, and a patent EP20315224.4 pending. Dr Goyard has a patent EP20315224.4 pending. Dr Janin has a patent EP20315224.4 pending. Dr Rose has a patent EP20315224.4 pending. Drs. Balbino, Liu, Poncet, and Bruhns have nothing to disclose. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.